JWJi S. Wang

Ji S. Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ji S. Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Ma

    Department of Hematology, Hematological Institute of Guizhou Province, Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Centre, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou, People's Republic of China

    2 shared publications
  • Qin Fang

    Department of Pharmacy, The Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China

    2 shared publications
  • Ling L. Ren

    Department of Hematology Affiliated Hospital of North Sichuan Medical College Nanchong China

    1 shared publication
  • Lingli Ren

    Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China

    1 shared publication
  • Liping Yang

    Clinical Medicine Research Center of Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China

    1 shared publication
  • Peng Zhao

    Department of Hematology Affiliated Hospital of Medical University Guiyang China

    1 shared publication

Latest Publications

  • Open Access

    HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia

    by Zhengchang He, Siyu Zhang, Dan Ma, Qin Fang, Liping Yang, Shaoxian Shen, Ying Chen, Lingli Ren, Jishi Wang

    Background: Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), and conventional chemotherapy (decitabine) does not effectively inhibit tumor cells. Enhancer of zeste homologue 2 (EZH2) and Heme oxygenase-1 (HO-1) are two key factors in patients resistance and deterioration. Methods: In total, 58 MDS patients were divided into four groups. We analyzed the difference in HO-1 and EZH2 expression among the groups by real-time PCR. After treatment with Hemin or Znpp IX, flow cytometry was used to detect apoptosis and assess the cell cycle distribution of tumor cells. Following injection of mice with very high-risk MDS cells, spleen and bone marrow samples were studied by immunohistochemistry (IHC) and hematoxylin and eosin (H&E) staining. MDS cells overexpressing EZH2 and HO-1 were analyzed by high-throughput sequencing. The effect of HO-1 on the pRB-E2F pathway was analyzed by Western blotting. The effects of decitabine on P15INK4B and TP53 in MDS cells after inhibiting HO-1 were detected by Western blotting. Results: Real-time PCR results showed that EZH2 and HO-1 expression levels were higher in MDS patients than in normal donors. The levels of HO-1 and EZH2 were simultaneously increased in the high-risk and very high-risk groups. Linear correlation analysis and laser scanning confocal microscopy results indicated that EZH2 was related to HO-1. MDS cells that highly expressed EZH2 and HO-1 infiltrated the tissues of experimental mice. IHC results indicated that these phenomena were related to the pRB-E2F pathway. High-throughput sequencing indicated that the progression of MDS to AML was related to EZH2. Using the E2F inhibitor HLM006474 and the EZH2 inhibitor JQEZ5, we showed that HO-1 could regulate EZH2 expression. HO-1 could stimulate the transcription and activation of EZH2 through the pRB-E2F pathway in MDS patients during chemotherapy, which reduced TP53 and P15INK4B expression. Conclusions: EZH2 was associated with HO-1 in high-risk and very high-risk MDS patients. HO-1 could influence MDS resistance and progression to AML.


  • Heme oxygenase‐1 attenuates the inhibitory effect of bortezomib against the APRIL‐NF‐κB‐CCL3 signaling pathways in multiple myeloma cells: Corelated with bortezomib tolerance in multiple myeloma

    by Zheng C. He, Xin Y. Li, Yong L. Guo, Dan Ma, Qin Fang, Ling L. Ren, Zhao Y. Zhang, Weili Wang, Zheng Y. Yu, Peng Zhao, et al.

    Osteoclasts (OCs) play an essential role in bone destruction in patients with multiple myeloma (MM). Bortezomib can ameliorate bone destruction in patients with MM, but advanced MM often resists bortezomib. We studied the molecular mechanisms of bortezomib tolerance in MM. The expression of the MM‐related genes in newly diagnosed patients with MM and normal donors were studied. C‐C motif chemokine ligand 3 (CCL3) is a cytokine involved in the differentiation of OCs, and its expression is closely related to APRIL (a proliferation‐inducing ligand). We found that bortezomib treatment inhibited APRIL and CCL3. But the heme oxygenase‐1 (HO‐1) activator hemin attenuated the inhibitory effects of bortezomib on APRIL and CCL3. We induced mononuclear cells to differentiate into OCs, and the enzyme‐linked immunosorbent assay showed that the more OCs differentiated, the higher the levels CCL3 secretions detected. Animal experiments showed that hemin promoted MM cell infiltration in mice. The weight and survival rate of tumor mice were associated with HO‐1 expression. Immunohistochemical staining showed that HO‐1, APRIL, and CCL3 staining were positively stained in the tumor infiltrating sites. Then, MM cells were transfected with L‐HO‐1/si‐HO‐1 expression vectors and cultured with an nuclear factor (NF)‐kappa B (κB) pathway inhibitor, QNZ. The results showed that HO‐1 was the upstream gene of APRIL, NF‐κB, and CCL3. We showed that HO‐1 could attenuate the inhibitory effect of bortezomib against the APRIL‐NF‐κB‐CCL3 signaling pathways in MM cells, and the tolerance of MM cells to bortezomib and the promotion of bone destruction are related to HO‐1.